Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15195MR)

This product GTTS-WQ15195MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15195MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8339MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ8864MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ10238MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ13908MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ3844MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ2188MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ9165MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ12704MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-21M18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW